JP6821050B2 - アデノシン誘導体を含む緑内障の予防及び治療用薬学的組成物 - Google Patents

アデノシン誘導体を含む緑内障の予防及び治療用薬学的組成物 Download PDF

Info

Publication number
JP6821050B2
JP6821050B2 JP2019547971A JP2019547971A JP6821050B2 JP 6821050 B2 JP6821050 B2 JP 6821050B2 JP 2019547971 A JP2019547971 A JP 2019547971A JP 2019547971 A JP2019547971 A JP 2019547971A JP 6821050 B2 JP6821050 B2 JP 6821050B2
Authority
JP
Japan
Prior art keywords
compound
adenosine
purine
diol
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019547971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511437A5 (https=
JP2020511437A (ja
Inventor
サンク イ
サンク イ
チョンウ パク
チョンウ パク
ヘア オク キム
ヘア オク キム
ヒウ イ
ヒウ イ
ミラ ユ
ミラ ユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Future Medicine Co Ltd
Original Assignee
Future Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Future Medicine Co Ltd filed Critical Future Medicine Co Ltd
Publication of JP2020511437A publication Critical patent/JP2020511437A/ja
Publication of JP2020511437A5 publication Critical patent/JP2020511437A5/ja
Application granted granted Critical
Publication of JP6821050B2 publication Critical patent/JP6821050B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019547971A 2017-03-21 2018-03-21 アデノシン誘導体を含む緑内障の予防及び治療用薬学的組成物 Active JP6821050B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020170035224A KR101805400B1 (ko) 2017-03-21 2017-03-21 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
KR10-2017-0035224 2017-03-21
PCT/KR2018/003274 WO2018174549A1 (ko) 2017-03-21 2018-03-21 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물

Publications (3)

Publication Number Publication Date
JP2020511437A JP2020511437A (ja) 2020-04-16
JP2020511437A5 JP2020511437A5 (https=) 2020-05-28
JP6821050B2 true JP6821050B2 (ja) 2021-01-27

Family

ID=60920336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019547971A Active JP6821050B2 (ja) 2017-03-21 2018-03-21 アデノシン誘導体を含む緑内障の予防及び治療用薬学的組成物

Country Status (8)

Country Link
US (2) US11185556B2 (https=)
EP (1) EP3603647B1 (https=)
JP (1) JP6821050B2 (https=)
KR (1) KR101805400B1 (https=)
CN (1) CN110381955A (https=)
AU (1) AU2018238996B2 (https=)
CA (2) CA3057277C (https=)
WO (1) WO2018174549A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101805400B1 (ko) 2017-03-21 2017-12-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
KR102007640B1 (ko) 2017-11-29 2019-08-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물
CN116350649A (zh) * 2021-12-28 2023-06-30 未来制药有限公司 预防和/或治疗胆管炎或由其引起的肝疾病的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003750A (es) 2006-10-06 2009-06-18 Univ Pennsylvania Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
WO2008108508A1 (en) * 2007-03-07 2008-09-12 Fm Therapeutics Co., Ltd. Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
WO2012125400A1 (en) * 2011-03-14 2012-09-20 Acorn Biomedical, Inc. Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases
KR101805400B1 (ko) * 2017-03-21 2017-12-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
KR101820909B1 (ko) * 2017-07-07 2018-01-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물

Also Published As

Publication number Publication date
JP2020511437A (ja) 2020-04-16
CA3057277C (en) 2022-07-26
AU2018238996A1 (en) 2019-10-24
EP3603647B1 (en) 2024-08-21
WO2018174549A1 (ko) 2018-09-27
US20200016186A1 (en) 2020-01-16
AU2018238996B2 (en) 2021-01-28
US20210386771A1 (en) 2021-12-16
EP3603647A4 (en) 2021-01-06
CA3159836C (en) 2026-02-10
US12083140B2 (en) 2024-09-10
KR101805400B1 (ko) 2017-12-07
US11185556B2 (en) 2021-11-30
CA3159836A1 (en) 2018-09-27
CA3057277A1 (en) 2018-09-27
CN110381955A (zh) 2019-10-25
EP3603647A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
JP7175525B2 (ja) アデノシン誘導体を含む非アルコール性脂肪肝炎、肝線維症及び肝硬変症の予防及び治療用薬学的組成物
US9018371B2 (en) Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
SI9520055A (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US7199127B2 (en) Purine nucleosides
US12083140B2 (en) Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
KR101396092B1 (ko) 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 약학적 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210105

R150 Certificate of patent or registration of utility model

Ref document number: 6821050

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250